Is tirzepatide safe to use? What the evidence and your own health picture both tell you

How the safety case for tirzepatide was built, and what 'licensed' actually means here

Before the MHRA granted a UK licence for tirzepatide as a weight-management medicine, it reviewed data from the SURMOUNT clinical programme, which randomised thousands of adults across multiple trials, including SURMOUNT-1 alone, which enrolled 2,539 participants over 72 weeks. That review set the terms of the licence, the eligible population, the starting dose, the contraindications, and the ongoing Black Triangle (▼) monitoring status, which means the MHRA continues to collect and assess real-world safety reports beyond the trial period.

The NHS medicines page for tirzepatide gives a plain-English breakdown of known side effects and cautions, and it's worth a read before your consultation. Licensing, in practical terms, means a regulator concluded that for the defined population, benefits outweigh risks under prescribed conditions. It does not mean risk-free for everyone. That gap is what a clinical assessment fills. You can read more about the broader safety picture in our tirzepatide safety overview.

The side effects most people actually encounter, and the ones that need urgent attention

Digestive side effects are the most reported: nausea, loose stools, constipation, indigestion, bloating and burping. They tend to peak in the first week or two after a new dose and settle as your body adjusts. Fatigue, headache and dizziness appear less often. Injection-site reactions (mild redness or tenderness at the site) are common and usually short-lived. Rotating injection sites between the abdomen, thigh and upper arm helps reduce them.

More serious effects are less common but important. Acute pancreatitis is among them. On 29 January 2026 the MHRA published a Drug Safety Update specifically for GLP-1 receptor agonist medicines (including tirzepatide) confirming pancreatitis as an infrequent but potentially serious risk. The symptom to act on: severe stomach pain that builds and radiates towards the back, with or without vomiting. This is not typical nausea from a dose increase. Stop taking the medicine and seek medical help promptly if it happens. If you want a fuller breakdown of what to expect week by week, our Mounjaro side effects guide covers this in detail.

Gallbladder problems, including gallstones, have also been reported in clinical trials. Signs include sharp pain in the upper right abdomen, especially after eating. Allergic reactions are rare; symptoms of a serious one (swelling of the face or throat, difficulty breathing) need immediate emergency help.

One practical habit worth building: before each weekly injection, briefly check the injection device is intact, within its expiry date, and that the liquid is clear and colourless. It takes less than a minute and catches the unusual cases where a pen has been stored incorrectly or damaged.

Who should think carefully before starting, and who should not use tirzepatide at all

Tirzepatide is not licensed for people under 18. It is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, the MHRA advises using effective contraception throughout treatment and for a period after stopping. Women taking oral contraceptive pills should be aware that tirzepatide can slow gastric emptying and temporarily reduce pill absorption: NHS England's guidance on weight-management injections recommends adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase.

A personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2), means tirzepatide is contraindicated. A history of pancreatitis, or certain gastrointestinal conditions, requires careful prescriber discussion before any decision is made. These are not edge-case scenarios, they are exactly the questions our prescribers work through at consultation. You can read more about suitability specifics in our guide to whether Mounjaro is safe to use for different health profiles. If you have further questions before or after treatment starts, our support team is available seven days a week.

When to get medical help, and how to report a suspected side effect

Most tirzepatide side effects don't need emergency care, but some do. Seek urgent medical attention if you experience: severe or persistent stomach pain, especially if it spreads to the back; signs of an allergic reaction such as swelling of the lips, face or throat; symptoms of significant dehydration from prolonged vomiting or diarrhoea (feeling faint, very little urine, extreme thirst); or sudden changes in vision.

If you're unsure whether what you're feeling is expected or not, contact our clinical aftercare team or your GP. Never feel you have to wait for a scheduled review if something feels wrong. Tirzepatide carries a Black Triangle status, which means reporting side effects is especially valuable right now, and if you're still forming a view on the medicine, our pages covering whether tirzepatide is safe, whether it is safe to take tirzepatide, and whether taking tirzepatide is safe for your circumstances may help you feel more confident going into that conversation. The MHRA Yellow Card scheme lets patients report suspected reactions directly, it takes a few minutes and contributes to the real-world evidence base that shapes future prescribing guidance.

A prescriber reviewing your notes can also reassess whether the current dose is right, or whether a pause is the safer path. That reassessment happens before every repeat order at nume's consultation service, so no repeat goes out on autopilot. If you're weighing up your options more broadly, our weight-loss treatment overview explains the range of approaches available.